These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 11036120)

  • 21. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.
    Oei HH; van der Meer IM; Hofman A; Koudstaal PJ; Stijnen T; Breteler MM; Witteman JC
    Circulation; 2005 Feb; 111(5):570-5. PubMed ID: 15699277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction.
    Sudhir K
    Vasc Health Risk Manag; 2006; 2(2):153-6. PubMed ID: 17319459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up.
    Brilakis ES; McConnell JP; Lennon RJ; Elesber AA; Meyer JG; Berger PB
    Eur Heart J; 2005 Jan; 26(2):137-44. PubMed ID: 15618069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study.
    White HD; Simes J; Stewart RA; Blankenberg S; Barnes EH; Marschner IC; Thompson P; West M; Zeller T; Colquhoun DM; Nestel P; Keech AC; Sullivan DR; Hunt D; Tonkin A;
    J Am Heart Assoc; 2013 Oct; 2(5):e000360. PubMed ID: 24152981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS).
    Lim PO; Yee KM
    Circulation; 1999 Aug; 100(6):686. PubMed ID: 10441109
    [No Abstract]   [Full Text] [Related]  

  • 26. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.
    Lindahl B; Toss H; Siegbahn A; Venge P; Wallentin L
    N Engl J Med; 2000 Oct; 343(16):1139-47. PubMed ID: 11036119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community.
    Gerber Y; McConnell JP; Jaffe AS; Weston SA; Killian JM; Roger VL
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2517-22. PubMed ID: 16902161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study.
    Luc G; Bard JM; Juhan-Vague I; Ferrieres J; Evans A; Amouyel P; Arveiler D; Fruchart JC; Ducimetiere P;
    Arterioscler Thromb Vasc Biol; 2003 Jul; 23(7):1255-61. PubMed ID: 12775578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?].
    Piñón P; Kaski JC
    Rev Esp Cardiol; 2006 Mar; 59(3):247-58. PubMed ID: 16712749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
    J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-density lipoprotein size, pravastatin treatment, and coronary events.
    Campos H; Moye LA; Glasser SP; Stampfer MJ; Sacks FM
    JAMA; 2001 Sep; 286(12):1468-74. PubMed ID: 11572739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS).
    Basso F; Lowe GD; Rumley A; McMahon AD; Humphries SE
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):599-604. PubMed ID: 11950697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
    Corson MA; Jones PH; Davidson MH
    Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.
    Lowe G; Rumley A; Norrie J; Ford I; Shepherd J; Cobbe S; Macfarlane P; Packard C
    Thromb Haemost; 2000 Oct; 84(4):553-8. PubMed ID: 11057849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study.
    West MJ; Nestel PJ; Kirby AC; Schnabel R; Sullivan D; Simes RJ; Pollicino C; Lubos E; Münzel TF; White HD; Tonkin AM; Bickel C; Tiret L; Blankenberg S;
    Eur Heart J; 2008 Apr; 29(7):923-31. PubMed ID: 18296678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
    Anderson JL
    Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cardiovascular event reduction tool (CERT)--a simplified cardiac risk prediction model developed from the West of Scotland Coronary Prevention Study (WOSCOPS).
    L'Italien G; Ford I; Norrie J; LaPuerta P; Ehreth J; Jackson J; Shepherd J
    Am J Cardiol; 2000 Mar; 85(6):720-4. PubMed ID: 12000046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
    Boekholdt SM; Keller TT; Wareham NJ; Luben R; Bingham SA; Day NE; Sandhu MS; Jukema JW; Kastelein JJ; Hack CE; Khaw KT
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):839-46. PubMed ID: 15692105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study.
    Brouilette SW; Moore JS; McMahon AD; Thompson JR; Ford I; Shepherd J; Packard CJ; Samani NJ;
    Lancet; 2007 Jan; 369(9556):107-14. PubMed ID: 17223473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.